Frontotemporal Dementia Linked to Chromosome 3 in Saccharomyces cerevisiae by Sulkko, Niles
University of Colorado, Boulder
CU Scholar
Undergraduate Honors Theses Honors Program
Spring 2013
Frontotemporal Dementia Linked to
Chromosome 3 in Saccharomyces cerevisiae
Niles Sulkko
University of Colorado Boulder
Follow this and additional works at: http://scholar.colorado.edu/honr_theses
This Thesis is brought to you for free and open access by Honors Program at CU Scholar. It has been accepted for inclusion in Undergraduate Honors
Theses by an authorized administrator of CU Scholar. For more information, please contact cuscholaradmin@colorado.edu.
Recommended Citation
Sulkko, Niles, "Frontotemporal Dementia Linked to Chromosome 3 in Saccharomyces cerevisiae" (2013). Undergraduate Honors
Theses. Paper 495.
Frontotemporal Dementia Linked to Chromosome 3 in Saccharomyces cerevisiae
by
Niles Sulkko
University of Colorado at Boulder
Department of Molecular, Cellular, and Developmental Biology
April 2013
Thesis Advisor: 
Dr. Greg Odorizzi, Department of Molecular, Cellular, and Developmental Biology
Defense Committee:
Dr. Jennifer Martin, Department of Molecular, Cellular, and Developmental Biology
Dr. Christopher Link, Department of Integrative Physiology
Abstract
Frontotemporal dementia (FTD) represents a crippling new neurodegenerative disease for 
scientific investigation. Marked by characteristic frontal and temporal lobar cortical atrophy, 
FTD results in the progressive deterioration of social and behavioral capabilities. FTD exhibits 
an autosomal dominant inheritance pattern, and is the second most common form of presenile 
dementia behind Alzheimer's disease. One subtype of the neuropathy, designated as 
frontotemporal dementia linked to chromosome 3 (FTD3), has been traced to a single truncating 
mutation in the human protein CHMP2B. Fortunately, S. cerevisiae ortholog Vps2 shares 
conserved function with CHMP2B, and functions analogously as a constituent of the ESCRT-
mediated endocytic pathway, necessary for protein trafficking and degradation within the cell. In 
order to investigate the mechanism and genetics behind FTD3 pathology, a corresponding 
mutation has been created in yeast, and a variety of assays examining its function have been 
conducted. This projects details the mutation’s potential effects on autophagy, as well as the 
critical polymerization of ESCRT-III component Snf7. Ultimately, this exposition suggests that 
autophagy is not affected by the FTD3 mutation. Additionally, heterozygous expression of 
mutated Vps2 does not appear to cause aberrant Snf7 polymerization, while haploid expression 
does seem to affect the process. Finally, proposed future experiments should continue to help 
resolve the mechanism behind frontotemporal dementia linked to chromosome 3.
Introduction
A Clinical Presentation of FTD
 Recent advancements in genetic testing and pedigree analysis have revealed a new type 
of debilitating neurodegenerative disease: frontotemporal dementia. Frontotemporal dementia, 
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known colloquially as FTD, exhibits an average age of onset in the late fifties, and is attributed 
to 20% of all dementia cases before the age of 65 (Skibinski et al., 2005). As a result, FTD 
represents the second most common cause of presenile dementia, behind Alzheimer's disease 
(Urwin et al., 2009). While all cases of FTD share the common characteristics of marked frontal 
and temporal lobar atrophy of the cerebral cortex, a variety of clinical symptoms are ascribed to 
specific categories of FTD. The most common designation, representative of 60% of FTD cases, 
is categorized as behavioral variant FTD (bvFTD) (Wittenberg et al., 2008). The hallmarks of 
bvFTD include distinct behavioral and emotional changes strikingly inconsistent with the 
patient's prior personality; apathy, disinhibition, impaired reasoning capacity, and a severe 
decrease in social abilities are all symptoms of bvFTD. In addition to bvFTD, two additional 
categories of FTD, characterized by pronounced language dysfunction, correspond to 
approximately 40% of all FTD cases. Progressive non-fluent aphasia (PNFA) FTD is categorized 
as FTD cases with severe impairment in speech production, yet intact comprehension of the 
meaning of words. In contrast, semantic dementia FTD results in deficits both in speech 
production and comprehension. In both cases, the progression of the disease often times 
decreases the capacity for empathy in patients, while additionally accompanied by the social and 
personality deficits observed in bvFTD (Hodges, 2001). Ultimately, cases of bvFTD and 
semantic FTD exhibit high rates of comorbidity in their diagnosis. The prognosis for all 
categories of FTD remains one marked by rapid onset followed by a steady neurological decline 
for 2-10 years before death. 
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Genetics of FTD
 New and ongoing investigations into the underlying genetic basis for frontotemporal 
dementia have made progress in elucidating the cause of the disease. Approximately 40% of 
FTD cases are familial, and the condition is inherited in an autosomal dominant pattern (Seelaar 
et al., 2011). Consequently, an afflicted parent presents a 50% probability in passing the genetic 
mutation to their progeny. The most common mutations implicated in FTD heredity are localized 
to two genes along the long arm of chromosome 17. Mutations occurring in the MAPT 
(microtubule-associated protein tau) loci result in a designation of frontotemporal subclass 
FTDP-17T (Talbot & Ansorge, 2006). Responsible for an estimated 10% of all FTD cases, 
mutations in the MAPT genes on chromosome 17 produce the detrimental aggregation of tau 
protein in neurons, ultimately resulting in neuronal degradation. Similar to many types of 
neurodegenerative disease, FTDP-17T is classified as having a clear pathology in relation to the 
protein tau, known as a “taupathy”. Comprising another approximate 10% of all FTD 
occurrences are those associated with null mutations in the PGRN (progranulin) gene, situated 
1.7Mb upstream of the MAPT loci (Snowden et al., 2006). PGRN, among its many putative 
roles, serves as a neuronal growth and viability factor. Unlike FTDP-17T, PGRN-associated FTD 
results in tau-negative, ubiquitin-positive inclusions in the afflicted neurons. Ultimately, PGRN 
cases are thought to be the result of haploinsufficiency, with the mutations in the gene resulting 
in “premature mRNA truncation and nonsense mediated decay” (Mackenzie et al., 2006).
 While the majority of FTD cases characterized thus far result from mutations in 
chromosome 17, a fascinating population has emerged linked to a single unique mutation on 
chromosome 3 (Van der Zee et al., 2008). First discovered in 1995 in the Jutland region of the 
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Netherlands, the pedigree of frontotemporal dementia linked to chromosome 3 (FTD3) spans 450 
members and can be linked across six generations of a single Danish family (Skibinski et al., 
2005). FTD3 is similar to PGRN-linked FTD in that both are tau-negative disease states with 
ubiquitinated inclusions (Talbot & Ansorge, 2006). However, unlike the majority of FTD cases 
where the primary ubiquitinated protein has been ascertained as TAR-binding protein 43 
(TDP-43), FTD3 shows no such similarities, and is subsequently classified as a TDP-43-negative 
variant of FTD (Filimonenko et al., 2007). Ultimately, it is the single, unambiguous mutation in 
FTD3 which provides an intriguing problem for study. FTD3 arises from a single point mutation 
in the protein CHMP2B (charged multivesicular body protein 2B) resulting in a marked guanine 
to cytosine transition in the acceptor splice site of exon 6 (Isaacs et al., 2011). As a consequence, 
two aberrant transcripts are produced, both exhibiting a truncation of 36 amino acids in the 
carboxyl terminus of CHMP2B (Urwin et al., 2009). The first, designated as CHMP2B^intron5, 
creates a novel valine amino acid residue followed by a stop codon (Figure 1). The second 
resulting transcript produces a frame-shift mutation, the result of which produces 29 amino acids 
of a non-functional nonsense sequence. 
 Fortunately, CHMP2B in humans shares an exact ortholog in yeast: vacuolar protein 
sorting gene, or Vps2. As such, the model organism Saccharomyces cerevisiae can be 
implemented as an effective functional disease model for investigation into the genetics and 
molecular mechanisms responsible for FTD3. S. cerevisiae presents a relatively easily 
manipulated genome, as well as the ability to exist in either a haploid or diploid form, a trait 
which allows for excellent genotype experimentation and analysis. In relation to cell biology, 
orthologous proteins CHMP2B and Vps2 perform known critical roles in endosomal membrane 
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trafficking. Both function in their respective organisms as a component protein in the assembly 
of the heteromeric protein complex ESCRTIII (Endosomal Sorting Complex Required for 
Transport-III), the third and final of the ESCRT complexes necessary for protein degradation, 
recycling, and endosome trafficking within the cell. In order to understand the putative disease 
mechanisms behind FTD3, the endocytic pathway and its function as facilitated by the ESCRTs 
must be examined.
The Endocytic Pathway and Critical ESCRTs
 The endocytic pathway represents an indispensable process in the trafficking and 
regulation of proteins away from the cell membrane and cytosol. This highly dynamic 
mechanism allows for the correct localization of cellular proteins to the endosome, where they 
are resigned to two potential fates. After initial budding into the early endosome, some proteins 
are recycled back to their area of function, often times back to the plasma membrane or golgi. 
This is often times the case for house-keeping receptors such as transferrin receptor, necessary 
for the maintenance of normal cell function (Russell et al., 2006). For other proteins, such as 
epidermal growth factor receptor (EGFR), uptake into the early endosome is the first step 
towards their ultimate degradation in the lysosome. As the early endosome matures to a late 
endosome, proteins targeted for degradation are facilitated into intraluminal vesicles (ILVs) 
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within the late endosome, creating a multivesicular body (MVB) (Raiborg & Stenmark, 2009). 
This progressive process is accompanied by both a change in membrane composition of the 
MVB and an increasingly acidic environment within the vesicle. Upon reaching its destination, 
the MVB finally fuses with the lysosome, resulting in the degradation of its lumenal contents. 
 The process of MVB biogenesis and protein degradation is conserved across all 
eukaryotes, and is orchestrated by a fascinating class of proteins deemed the endosomal sorting 
complexes required for transport, or simply ESCRTs (Babst, 2005). Also implicated in retroviral 
budding and the final scission step in cytokinesis, the ESCRT machinery is composed of four 
sequential heteromeric protein complexes, starting with ESCRT-0 and ending with ESCRT-III. 
First, a target protein is ubiquitinated on its cytosolic surface and endocytosed via the clathrin 
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complex to form an early endosome within the cell. At this juncture, proteins destined for 
recycling are returned to their site of action, while proteins marked for degradation are 
recognized as such by ESCRT-0. ESCRT-0 is recruited to the endosome surface via its binding to 
the endosomal membrane phospholipid phosphatidylinositol 3-phosphate (PtdIns-3-P), and is 
thought to help concentrate the protein cargo (Teis et al., 2010). Next, the ESCRT-I complex 
binds to the ubiquitinated endosomal cargo, which in turn activates and recruits ESCRT-II to the 
action site. The recruitment of both ESCRT-I and ESCRT-II is concentrated to the neck of the 
forming invagination, and together are thought to ultimately deform the endosomal membrane 
and induce ILV budding into the lumen (Hurley & Hanson, 2010). At last, the catalysis of the 
final scission event of the ILV into the lumen of the endosome is accomplished via ESCRT-III. In 
this process, Vps25 of ESCRT-II recruits Vps20, the vanguard of ESCRT-III, to the forming 
invagination. Vps20 nucleates the homo-oligomerization of the the most prevalent ESCRT-III 
component Snf7, whose assembly and subsequent capping by Vps24 effectively “pinches” off 
the budding vesicle into the lumen (Wollert et al., 2009). In addition to terminating Snf7 
assembly, Vps24 then activates and associates with Vps2 (CHMP2B), the mutated protein in 
FTD3. At last, Vps2 recruits the AAATPase Vps4, which through the hydrolysis of ATP catalyzes 
the disassembly of the entire ESCRT complex, liberating all components for subsequent rounds 
of protein trafficking.
Sulkko 8
Current Data on Vps2∆FTD3 and Project Aim
 Ultimately, by integrating what is known about the ESCRT mediated endocytic pathway, 
the specific mutation of Vps2 in FTD3 (Vps2∆FTD3), and recently acquired experimental data, 
this exposition details an investigation into the mechanistic basis for chromosome-3 linked 
frontotemporal dementia. In truncating the last 36 amino acids of Vps2, Vps2∆FTD3 results in 
the elimination of two key protein motifs necessary for ESCRT-III function. All ESCRT-III 
proteins in their wild-type form include a conserved negatively-charged autoinhibitory domain at 
their respective carboxy-termini (Wollert et al., 2009). This domain enables the ESCRT-III 
components to exist as soluble cytosolic monomers when not assembled to budding endosomal 
membrane. In Vps2∆FTD3, this auto-inhibitory domain is eliminated, and recent studies have 
indicated that afflicted cells showcase hyperactive Vps2∆FTD3 assembly at the endosome 
membrane (Lee). Additionally, Vps2 utilizes a MIT interacting motif (MIM1) along its C-
terminus in its interaction with Vps4 and its inherent microtubule interacting and transport (MIT) 
domain (Teis et al., 2009). Consequently, Vps2 is responsible for the recruitment and stimulation 
of Vps4, which via AATPase activity, allows for the disassembly of the ESCRT-III complex and 
Sulkko 9
ensures subunit availability for subsequent rounds of protein degradation. The Vps2∆FTD3 
mutation omits the MIM1 region of Vps2, therefore eliminating its ability to recruit Vps4.
 Recently, researcher Ian Smith in the Odorizzi laboratory examined the effects of 
Vps2∆FTD3 using electron tomography and fluorescent microscopy, investigating the mutation’s 
ramifications in both haploid (Vps2∆FTD3) and heterozygous diploid (VPS2/FTD3) genotypes. 
In wild-type cells, electron tomography reveals cells with functional MVBs complete with 
distinct ILV’s, often times in close proximity to their ultimate destination of the vacuole. In cells 
with an ESCRT-III null mutation, functional MVB’s are replaced with aberrant endosomal 
structures known as class E-compartments. These abnormal formations take on a characteristic 
cisternal-like appearance and are the morphological hallmark of ESCRT-III dysfunction. Ian’s 
electron microscopy data revealed that in haploid cells, the expression of a single mutated allele 
of Vps2∆FTD3 results in the formation of E-compartments, a phenocopy of an ESCRT-III null 
mutation. While heterozygous cells expressing only one copy of Vps2∆FTD3 exhibited MVB’s 
and the absence of E-compartments, tomographs suggestive of a delay in ILV budding provide 
further evidence of an ESCRT implicated dysfunction. Next, fluorescent microscopy was 
employed to examine Vps2∆FTD3’s effect on protein localization and cargo sorting. As early 
endosomes mature to late endosomes and cargo is facilitated into ILVs, the initial membrane 
constituent Rab GTPase, Rab5, is exchanged for its predecessor, Rab7. This conversion, 
represented by the transfer of Vps21 for Ypt7 in yeast, serves as a unique marker for endosome 
maturation, and is necessary for efficient fusion with the vacuole (Russell et al., 2006). When 
both Rab GTPases were tagged with GFP and monitored for localization in heterozygous VPS2/
FTD3 cells, both exhibited regular sorting. However, a heterozygous background did alter the 
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sorting of carboxypeptidase S (CPS), a transmembrane protein normally delivered to the vacuole 
for degradation. Vps2/FTD3 cells caused an accumulation of GFP marked puncta along the 
periphery the vacuole, indicative of abnormal late endosome accumulation. This data suggests a 
delay of some sort in endosome-lysosome fusion, and a potential consequence of the VPS2/
FTD3 background. 
 Finally, data from other labs has supported our findings thus far, and has implicated a 
new potential malfunctioning pathway in FTD3, autophagy. In examining both mammalian cell 
models and Drosophila melanogaster, recent studies report that an ectopic overexpression of 
aberrant Vps2∆FTD3 results in the abnormal accumulation of both late endosomes (MVBs) and 
autophagosomes (Filimonenko et al., 2007, Lee et al., 2007). This information suggests that 
Vps2∆FTD3 may hinder autophagic processing. Similar to endosome mediated protein 
degradation, autophagy provides a mechanism for the breakdown of cytosolic contents and 
organelles, and is heavily implicated in cellular response to stress and starvation conditions 
(Yang & Klionsky, 2010). Importantly, an impairment of autophagy results in neurodegeneration 
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in mice (Urwin et al., 2009), and its study hold promise in understanding human 




 The standard utilization of PCR-based gene deletion cassettes was used in the 
construction in all Vps2∆FTD3 strains, as well as autophagy mutant strains. Ploidy of diploid 
strains was confirmed via halo assay. Wild-type and vps4∆ controls were restreaked from -80˚C 
onto standard YPD agar plates.
Autophagic Flux Assay:
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 All assayed strains were transformed with a regular expression GFP-Atg8 plasmid 
(SLS5916), and plated on selectable marker -URA plates. Transformants were then grown in 
YNB-URA  at 30˚C to saturation overnight. Saturated cultures were cut back to .20 ODU and 
allowed to grow for 1.5 hours. Next, strains designated for autophagy induction were treated 
with rapamycin at a concentration of .2ug/ml, and all strains were allowed to incubate for an 
additional three hours. Following incubation, cells were collected, subject to glass bead lysis, and 
TCA precipitated. Protein samples were resuspended in 1X SDS-PAGE sample buffer +.2% 
BME, and .5 OD600 units were resolved on large 12% SDS-polyacrylimide gels. Protein transfer 
to nitrocellulose membrane was done overnight, and resulting membrane was blocked for 1.5 
hours in 10% milk/TBST. Primary mouse anti-GFP antibody was administered at a 1:2000 
dilution overnight. Following three five minute washes with .05% TBST, mouse specific HRP-
conjugated secondary was applied for 3 hours. Two more TBST washes followed by a final TBS 
wash prepared the membrane for chemiluminescent visualization on x-ray film. An X-ray 
exposure time of 45 minutes was implemented.
Snf7 Polymerization Assay:
 Before cellular lysates were harvested, the linear glycerol gradients were prepared. 10%, 
20%, 30% and 40% stocks of glycerol were made up in PBS +.5% Tween 20. A separate gradient 
was poured concurrently for each cell strain. First, 2.5 mls of 40% glycerol was pipetted into a 
test tube. Very slowly, 2.5 mls of the 30% glycerol was layered on top, followed by 2 mls of the 
20% glycerol. Next, a mixture of the 10% glycerol/lysis buffer/1% Triton X-100/PIC solution 
topped the gradient. To convert the gradients from step to linear gradients, a pre-spin at 30,000 
rpm for one hour was done.
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 All examined strains were grown to saturation overnight in YPD, and cut back to  .20 
ODU in 50 ml of the same media. Once cells reached mid-logarithmic growth phase they were 
harvested, washed, spheroplasted and dounced. Unbroken cells were removed following a 3 
minute spin at 3000 rpm. The P13 fragment was solubilized in 1-ml of PBS+0.5% Tween, and 
passed through a 25G5/8 needle five times before a 10 minute spin at 13000 rpm. Finally the 
supernatant, corresponding to 30 OD600 units of each cell strain, was delicately loaded on top of 
the ready glycerol gradients. Each loaded gradient was subject to a 4 hour 100000 x g 
centrifugation at 4˚C. Upon completion of centrifugation, 11 distinct 1-ml fractions were 
collected from each gradient run, with the first fraction corresponding to lowest glycerol density. 
Each fractionation was subject to TCA protein precipitation, with each pellet resuspended via 
sonication in 1X SDS-PAGE sample buffer +.2% BME. In total, 25 ul of each fractionation was 
loaded in descending order onto a 10% SDS-polyacrylimide gel. Subsequent western blot 
protocol mirrors the procedure previously described in “Autophagy Flux Assay” with the 
following exceptions. Snf7 antisera was used as the primary antibody, and rabbit specific HRP-
conjugated secondary was applied. Additionally, an x-ray exposure time of 15 minutes was 
sufficient for detection.
 Size standards for the 10%–40% glycerol gradient were previously established by 
graduate student Natalie Johnson by examining the localization of aldolase (156 kD), catalase 
(232 kD), ferritin (440 kD) and thyroglobulin (670 kD). Wild-type and Vps4∆ polymerization 
results were supplied by Natalie Johnson and allowed for insight into the assembly pattern of 
healthy and ESCRT-III dysfunctional cells.
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Results
Autophagic processing of GFP-Atg8 is unaffected in Vps2∆FTD3 mutants
 As recent data reports a marked accumulation of autophagosomes as a consequence of 
ectopic over-expression of mutated Vps2∆FTD3, the autophagic pathway represents a key target 
for research. In order to investigate Vps2FTD3’s potential effects on the autophagic process, an 
experiment monitoring the processing of the chimeric protein GFP-Atg8 was conducted. Upon 
the induction of autophagy, the ubiquitin-like autophagy-related protein 8 (Atg8) becomes tightly 
associated with the inner vesicle of the double membraned autophagosome, where it is ultimately 
transported to the vacuole for degradation (Xie et al., 2008). Fortunately, tagging the amino 
terminus of Atg8 with green fluorescent protein (GFP) offers a convenient way for analyzing 
autophagy. The GFP tag does not interfere with Atg8 localization, and the chimeric version is 
similarly brought to the vacuole for degradation. In contrast to Atg8, GFP is relatively resistant to 
proteolysis and is released from Atg8 as free GFP in the vacoule. Consequently, the appearance 
of free GFP and its corresponding molecular weight can be detected via western blot and 
compared to levels of non-processed chimera (Tomohiro Yorimitsu et al., 2009). 
 Seven different yeast strains and subsequent genotypes were monitored for autophagy 
processing. Three of the strains were subjected to PCR-mediated gene deletion of the protein 
Atg1. The deletion of Atg1 effectively blocks the induction of autophagy and provides bona-fide 
examples of non-functional mutants for the autophagic pathway (T Yorimitsu & Klionsky, 2005). 
The inclusion of two wild-type strains, one haploid and one diploid, allows for an observable 
control. Of primary focus was the haploid and diploid mutants expressing truncated 
Vps2∆FTD3. Following their creation and confirmation of their respective genetic background, 
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all strains were transformed with a regular copy plasmid expressing GFP-Atg8. Autophagy was 
induced via rapamycin treatment in each strain genotype, with a counterpart strain receiving no 
drug. Each culture was subject to trichloroacetic acid (TCA) protein precipitation, resolved via 
SDS-PAGE, and probed for GFP using standard western blot protocol. 
 Ultimately, both wild-type haploid and diploid yeast strains showcased processing of the 
chimeric GFP-Atg8 protein. Rapamycin treatment and consequent autophagy induction increased 
visible free GFP in both backgrounds, but was also accompanied by a basal, albeit reduced, level 
of autophagy in untreated counterparts. As expected, all Atg1 knockout strains exhibited a 
complete inability to undergo autophagy, and no free GFP was detected. This result was also 
replicated in a strain heterozygous for the FTD3 truncation with accompanying homozygous 
Atg1 knockouts. Finally, haploid Vps2∆FTD3 showcased results similar to wild-type controls, 
with autophagy occurring in both the uninduced and rapamycin treated strains, with a slight 
increase observed in the latter. The heterozygous strain for the FTD3 mutation did not exhibit 
impaired autophagy, and free GFP was detected following treatment with rapamycin. Non-
treated heterozygous VPS2/Vps2∆FTD3 did not show free GFP detectable via western blot, an 
observation unique in the context of functional Atg1.
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Snf7 polymerization is affected in haploid, but not diploid Vps2∆FTD3 mutants
 Vps2 represents an essential component in the function of the ESCRT-III complex on late 
endosomes. Wild-type Vps2 functions in conjunction with Vps20 to cap and terminate the 
homooligomerization of Snf7, the main driver of ILV scission into the endosome. Vps2 
additionally recruits and stimulates the AATpase Vps4, which in turn catalyzes the dissociation 
of the ESCRT-III complex. As a result, a sizing analysis assay was performed in order to monitor 
potential effects of Vps2∆FTD3 on the polymerization of Snf7. Both haploid and heterozygous 
diploid strains for Vps2∆FTD3 were examined, in conjunction with a wild-type diploid control. 
Unpublished data from Odorizzi laboratory graduate student Natalie Johnson was employed to 
validate experimental wild-type controls, establish protein size standards, as well provide a 
comparative example of aberrant Snf7 polymerization as exhibited in a Vps4∆ strain.
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 In order to conduct the experiment, cultures of all three strains were harvested, 
spheroplasted, and subjected to sub-cellular fractionation to enrich for membranes. The 
solubilized membrane fractions (P13) were then subject to a 10%–40% glycerol velocity 
sedimentation gradient. 11 different size fractionations were harvested from each cell strain, 
trichloroacetic acid (TCA) precipitated, resolved via SDS-PAGE, and probed with Snf7 specific 
antisera. The distribution of Snf7 along the density gradient was examined in order to ascertain 
potential effects of the FTD3 mutation.
 Consistent with established control data from the lab, the wild-type diploid strain 
showcased two distinct populations of Snf7 at endosomes, corresponding to both a monomer and 
polymer population. At approximately the 156 kilodaltons (kD) fraction, a robust band was 
resolved as representative of the Snf7 monomer at the first fraction on the gradient. A 
characteristic Snf7 polymer was found distributed at a higher density region, corresponding to a 
heavier molecular weight. In contrast, the haploid strain expressing Vps2FTD3 showcased some 
level of Snf7 detection in each of the 11 fractions. Two regions of noticeable Snf7 concentration 
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occurred at approximately 232kD, as well as the terminal two fractions of the gradient. These 
two regions of increased Snf7 accumulation may correspond to the monomer and polymer of 
Snf7 assembly. An increased Snf7 detection at the higher density fractions resembles the 
detection assay characteristic of a Vps4 knockout strain. Vps4∆ strains lack the ability to 
dissociated the ESCRT-III complex, and remain constituently assembled. Finally, heterozygous 
VPS2/Vps2∆FTD3 exhibited a Snf7 polymerization pattern similar to the wild-type control. A 
clear monomeric accumulation of Snf7 was shown in the lowest density fraction taken, and 
supplemented by an inferred polymeric complex at a separate, denser section of the blot. No 




 The mutation of Vps2 involved in chromosome 3-linked frontotemporal dementia 
(FTD3) implicates a variety of different cellular processes as potential causes of the 
neurodegenerative disease. One such cellular mechanism, the autophagic pathway, has recently 
been suggested as a prospective cause for the pathology described in humans. Autophagy serves 
as the predominant method of bulk degradation for organelles and soluble cytosolic proteins, and 
is highly conserved amongst eukaryotes. This process is facilitated by the formation of the 
double membraned autophagosome, which sequesters cargo within its internal vesicular lumen 
and is trafficked to the vacuole for degradation. The autophagosome may be transported directly 
to the vacuole, or alternatively, the autophagosome may fuse with a mature late endosome, 
forming a hybrid amphisome, which is then transported to the vacuole (Figure 5) (T Yorimitsu & 
Klionsky, 2005). Defects in autophagy have been linked to a variety of neurodegenerative 
diseases, including Alzheimer's, Huntington's, and Parkinson's disease (Rusten & Stenmark, 
2009). These pathologies are hypothesized to result from an insufficient degradative clearing of 
proteins, resulting in detrimental aggregation in afflicted neurons.   
 In the case of FTD3, ectopic over-expression of Vps2∆FTD3 results in a marked 
accumulation of autophagosomes and late endosomes in mammalian and fly cell models. 
Importantly, this phenotype is replicated in ESCRT-depleted cells, and consequently leads to the 
hypothesis that not only are the ESCRTs required for efficient autophagy, but also that mutated 
Vps2∆FTD3 may be responsible for aberrant autophagy in FTD3. Specifically, the increased 
number of autophagosomes could be a consequence of decreased autophagic processing. In order 
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to test this theory, autophagic flux was assayed in haploid and FTD3 heterozygous mutants. 
Autophagy response was compared alongside bone-fide autophagy mutants incapable of 
initiating autophagy, as well as wild-type controls. Should expression of Vps2∆FTD3 affect the 
pathway, its western blot detection would closer resemble the autophagy mutants than wild-type 
controls. 
 Ultimately, our results indicate expression of either haploid or heterozygous diploid 
Vps2∆FTD3 does not significantly effect rapamycin-induced autophagic processing of chimeric 
GFP-Atg8. This experiment was repeated in triplicate, with each trial yielding parallel results. In 
the context of functional Atg1, autophagy was successfully induced, and free GFP was detected 
in all pertinent strains. In contrast, all functional knockouts of Atg1 resulted in no free GFP, 
consistent with Atg1’s irreplaceable role in autophagy initiation. 
 While our results indicate that Vps2∆FTD3 does not cause a decrease in autophagic 
processing, and consequently is not a substantiated cause of observed autophagosome 
accumulation, other alternative explanations exist. For example, aberrant autophagosome 
accumulation may be the result of enhanced initiation of the autophagic pathway, as opposed to 
faulty autophagosome-vacuole fusion. It is important to note that the relationship between 
ESCRTs and the autophagic pathway is only beginning to be investigated, and their association 
with one another is still unclear. Subsequently, the mutation in Vps2∆FTD3 may directly affect 
only the ESCRTs, yet in turn have an indirect effect on autophagy. With faulty endocytic cargo 
trafficking in the ESCRT mediated endocytic pathway, unknown intracellular signals may result 
in an increase in autophagy, executed in a ‘rescue-attempt’ to compensate for deficient protein 
trafficking. Such a response could logically cause an up-regulation in autophagosome formation, 
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and likely result in the observed phenotype. Additionally, the Vps2∆FTD3 mutation may 
ultimately affect the bioavailability of specific nutrients needed for regular cell function, as 
ESCRTs aid in the regulation of transmembrane receptors at the cell surface, such as the 
transferrin receptor. Aberrant Vps2∆FTD3 could ultimately result in a response associated with 
inefficient nutrients, which is a well-characterized initiator of autophagy. In turn, an up-
regulation of autophagosomes could result in an increase in protein degradation and subsequently 
combat starvation. Needless to say, additional studies are needed in order to fully resolve 
Vps2∆FTD3’s role in autophagy.
Vps2∆FTD3 and Snf7 Polymerization
 Principle amongst its functions, Vps2 represents a well-characterized constituent of the 
ESCRT-regulated endocytic pathway. A member of the final heteromeric ESCRT-III complex, it 
functions in two well-known roles. First, following vesicular bud formation, it associates with 
Vps24 to form a capping mechanism that terminates the oligomerization of Snf7, a process 
credited for catalyzing ILV scission into the late endosome. It then subsequently utilizes its 
MIM1 domain to bind the MIT portion of Vps4. This protein-protein interaction galvanizes the 
AATpase activity of Vps4, and the hydrolysis of ATP results in the disassembly of the ESCRT-III 
polymer allowing for future rounds of ILV scission. As such, the mutation of Vps2 in 
chromosome-3 linked frontotemporal dementia has yielded strong evidence to support the 
hypothesis that it causes dysfunction in the endocytic process.
 Unpublished fluorescent microscopy and electron tomography data from the Odorizzi lab 
has implicated protein missorting, aberrant vesicle morphology, and a potential delay in ILV 
budding resulting from Vps2FTD3. Outside data affirms these observations, reporting that the 
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ectopic over-expression of Vps2∆FTD3 leads to an abnormal accumulation of late endosomes at 
the vacuole periphery. This information leads to the hypothesis that Vps2∆FTD3 may interfere 
with the polymerization or ultimate disassembly of the Snf7 oligomer. Of all the ESCRT-III 
proteins, Snf7 is the only one shown to be absolutely imperative in ILV severing, a process 
which data suggests is delayed in FTD3. Additionally, the truncation in Vps2∆FTD3 removes its 
MIM1 domain, which is necessary in the enlistment of Vps4. Without Vps4, Snf7 and the entire 
ESCRT-III complex becomes trapped as an assembled complex at the endosome membrane 
(Wemmer et al., 2011). Ultimately, a Snf7 specific sizing assay was performed in order to test 
how Vps2∆FTD3 affects the polymerization of Snf7.
 Overall, our results indicate that haploid Vps2∆FTD3 produces abnormal Snf7 
polymerization, while in contrast heterozygous VPS2/Vps2∆FTD3 cells exhibit healthy Snf7 
polymerization consistent with wild-type cells. In the case of the heterozygous diploid and wild-
type controls, a clear Snf7 monomer at the lowest density fractionation suggests monomeric Snf7 
is recruited and available for assembly as needed to form ILVs. Higher density fractions 
represent the transient polymer present in a wild-type context. As for haploid Vps2∆FTD3, Snf7 
assembly is showcased at every probed molecular weight level. Two regions of increased Snf7 
detection, one region above and the other below the transient wild-type polymer, indicate some 
level of Snf7 polymer formation, but both differ from wild-type in their size. Additionally, when 
compared to a nonfunctional Vps4 blot in which ESCRT-III is unable to disassemble, both 
exhibit marked detection at the highest density fractions. This is suggestive that the truncation in 
some part enhances the formation or hinders the release of Snf7. At the time of this exposition, 
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this experiment has been conducted though its first trial, and additional trials will further 
elucidate Vps2FTD3’s effect on Snf7 oligomerization.
 Altogether, Vps2∆FTD3 does seem to effect Snf7 polymerization when a truncated 
version represents the sole expressed form. This finding is in accordance with electron 
tomography images, which showcase haploid cells with aberrant E-compartments in place of 
healthy MVB’s. However, as heterozygous expression does not seem to alter Snf7 activity, it 
seems unlikely that this mechanism alone can account for the pathology seen in humans. As the 
Vps2∆FTD3 mutation removes both its innate auto-inhibitory regions and protein interaction 
domains, a variety of assays are required to distinguish the exact mechanism of pathology.
Future Direction
 When considered together, the autophagy and Snf7 polymerization assays of this study 
suggest that the central pathology behind FTD3 remains unclear. Autophagic flux as monitored 
by the cleavage of chimeric marker GFP-Atg8 does not appear altered in haploid or heterozygous 
diploid strains expressing Vps2∆FTD3. Additionally, altered polymerization of Snf7 is observed 
in haploid Vps2∆FTD3, yet diploid VPS2/Vps2∆FTD3 seems sufficient in maintaining a healthy 
assembly pattern. These results provide inspiration for a new complement of experiments, which 
should help further resolve the mechanism underlying FTD3. In terms of monitoring autophagy, 
the next step is to employ fluorescent microscopy to examine the localization of GFP-Atg8 in 
Vps2∆FTD3 afflicted, autophagic cells. Upon rapamycin-induced autophagy, previous studies 
have found GFP-Atg8 to localize to the vacuole, a process facilitated by either autophagosome-
endosome fusion or direct autophagosome-vacoule fusion. A mislocalization of GFP-Atg8 in 
Vps2∆FTD3 would provide supporting evidence of a defect in the autophagic pathway, and a 
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potential contributing cause behind FTD3. Pertaining to the Snf7 polymerization assay, 
additional trials should be repeated in order to confirm our initial findings. Auxiliary experiments 
are also necessary in order to pinpoint other potential malfunctioning ESCRT-III subunit 
interactions. To accomplish this, in vivo native immunoprecipitation or in vitro pulldown assays 
can be implemented to discern both wild type and mutated Vps2∆FTD3’s binding partners. 
Differing protein interactions or expression levels in FTD3 afflicted cells would provide new 
evidence for altered ESCRT-III activity as the mechanism for pathology. Finally, more work 
investigating the potential for a malfunctioning Rab GTPase conversion event must be done. As 
endosomes mature from early endosomes to ILV-containing late endosomes (MVBs), the 
membrane constituent Rab5 is exchanged for its predecessor Rab7. Rab7, in addition to serving 
as an endosome maturity marker, is required for both endosome and autophagosome fusion with 
the vacuole. Despite preliminary fluorescent microscopy evidence that heterozygous 
Vps2∆FTD3 does not change localization of either Rab, this key pathway remains a likely target 
for dysfunction in FTD3. As such, sample lysates have already been prepped for work with 
Odorizzi lab collaborator Dr. Alex Merz at the University of Washington, who will investigate 
the biochemical status of Rab5 and Rab7 in FTD3 impaired cells. 
 Finally, the findings detailed in this thesis, accompanied by future prospective 
experiments, should provide key insight behind Vps2∆FTD3’s effect on cell function. 
Autophagy, ESCRT-III interactions, and Rab conversion with their potential malfunction all 
present intriguing projects in the investigation of the FTD3 mutation. Ultimately, further 
scientific examination should yield new understanding into both the basic science of Vps2 and 
the ESCRTs, as well as the mechanism behind frontotemporal dementia linked to chromosome 3.
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